Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: BMS-650032
DRUG: BMS-650032
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: Peginterferon Alfa-2a
DRUG: Peginterferon Alfa-2a
DRUG: Ribavirin
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb